Display options
Cite
Dehbanipour R, Rastaghi S, Sedighi M, et al. High prevalence of multidrug-resistance uropathogenic Escherichia coli strains, Isfahan, Iran. J Nat Sci Biol Med. 2016;7(1):22-6doi: 10.4103/0976-9668.175020.
Dehbanipour, R., Rastaghi, S., Sedighi, M., Maleki, N., & Faghri, J. (2016). High prevalence of multidrug-resistance uropathogenic Escherichia coli strains, Isfahan, Iran. Journal of natural science, biology, and medicine, 7(1), 22-6. https://doi.org/10.4103/0976-9668.175020
Dehbanipour, Razieh, et al. "High prevalence of multidrug-resistance uropathogenic Escherichia coli strains, Isfahan, Iran." Journal of natural science, biology, and medicine vol. 7,1 (2016): 22-6. doi: https://doi.org/10.4103/0976-9668.175020
Dehbanipour R, Rastaghi S, Sedighi M, Maleki N, Faghri J. High prevalence of multidrug-resistance uropathogenic Escherichia coli strains, Isfahan, Iran. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):22-6. doi: 10.4103/0976-9668.175020. PMID: 27003964; PMCID: PMC4780161.
Copy Download .nbib Format: NLM
Share it on

J Nat Sci Biol Med. 2016 Jan-Jun;7(1):22-6. doi: 10.4103/0976-9668.175020.

High prevalence of multidrug-resistance uropathogenic Escherichia coli strains, Isfahan, Iran.

Journal of natural science, biology, and medicine

Razieh Dehbanipour, Sedighe Rastaghi, Mansour Sedighi, Nafiseh Maleki, Jamshid Faghri

Affiliations

  1. Department of Microbiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
  2. Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Tehran, Iran.
  3. Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

PMID: 27003964 PMCID: PMC4780161 DOI: 10.4103/0976-9668.175020

Abstract

BACKGROUND AND OBJECTIVES: Urinary tract infection (UTI) is one of the most frequent infectious diseases and can occur in all age groups. Escherichia coli is the main cause of this infection. Multiple resistances to antimicrobial agents are increasing quickly in E. coli isolates and may complicate therapeutic strategies for UTI. The aim of this study was to determine the antibiotic resistance pattern and the multidrug-resistance (MDR) phenotypes in uropathogenic E. coli (UPEC).

MATERIALS AND METHODS: A total of 135 UPEC isolates were collected from both outpatients (91 isolates) and inpatients (44 isolates) between September, 2012 and February, 2013. In order to determine the MDR among UPEC isolates, we have tested 15 antimicrobial agents and antibiotic susceptibility was done by Kirby-Bauer disk diffusion method.

RESULTS: The percentage of MDR isolates (resistant to at least three drug classes such as aminoglycosides, fluoroquinolones, penicillins, cephalosporins, or carbapenems) was 68% in the inpatients and 61% in the outpatients. Antibiotic resistance to ampicillin, ceftazidim, nalidixic acid, and trimethoprim/sulfamethoxazole were higher than 50%. Amikacin, nitrofurantoin, and gentamicin showed markedly greater activity (89.1%, 85.9%, and 82.4% sensitivity, respectively) than other antimicrobial agents. Resistance to meropenem did show either in outpatients or in inpatients.

INTERPRETATION AND CONCLUSIONS: The high prevalence of drug resistance among UTI patients calls for continuous monitoring of the incidence of drug resistance for appropriate empiric selection of antibiotic therapy. Empirical treatment of UTIs should be relied on susceptibility patterns from local studies.

Keywords: Antimicrobial resistance; Escherichia coli; multidrug resistance; urinary tract infections

References

  1. Asian Pac J Trop Biomed. 2013 Apr;3(4):315-24 - PubMed
  2. Clin Infect Dis. 2011 Mar 1;52(5):e103-20 - PubMed
  3. BMJ. 2007 Aug 25;335(7616):395-7 - PubMed
  4. Med Sci Monit. 2007 Jun;13(6):BR136-44 - PubMed
  5. Antimicrob Agents Chemother. 2001 May;45(5):1402-6 - PubMed
  6. Nepal Med Coll J. 2005 Dec;7(2):116-8 - PubMed
  7. Jundishapur J Microbiol. 2014 May;7(5):e9936 - PubMed
  8. Indian J Med Res. 2012 Nov;136(5):842-9 - PubMed
  9. J Infect Chemother. 2005 Feb;11(1):44-7 - PubMed
  10. Indian J Med Res. 2014 Jun;139(6):945-8 - PubMed
  11. Bioinformation. 2014 Jul 22;10(7):419-22 - PubMed
  12. Urologe A. 2011 Feb;50(2):153-69 - PubMed
  13. BMC Vet Res. 2006 Feb 06;2:7 - PubMed
  14. Postgrad Med J. 2005 Feb;81(952):83-6 - PubMed
  15. Ned Tijdschr Geneeskd. 2006 Apr 1;150(13):718-22 - PubMed
  16. Rev Inst Med Trop Sao Paulo. 2008 Sep-Oct;50(5):255-60 - PubMed
  17. BMC Res Notes. 2012 Jan 19;5:38 - PubMed
  18. J Basic Clin Pharm. 2011 Dec;3(1):225-8 - PubMed
  19. J Bras Nefrol. 2013 Apr-Jun;35(2):93-8 - PubMed
  20. Rev Urol. 2013;15(2):41-8 - PubMed
  21. BMC Infect Dis. 2013 Jan 18;13:19 - PubMed
  22. PLoS One. 2014 Jan 28;9(1):e86634 - PubMed
  23. J Res Med Sci. 2014 Sep;19(9):899-903 - PubMed
  24. Diagn Microbiol Infect Dis. 2007 Dec;59(4):439-45 - PubMed
  25. Front Microbiol. 2014 Sep 18;5:463 - PubMed
  26. Emerg Infect Dis. 1999 Jan-Feb;5(1):18-27 - PubMed
  27. Saudi Med J. 2003 Mar;24(3):261-4 - PubMed
  28. Pediatrics. 2011 Sep;128(3):595-610 - PubMed
  29. Infection. 2007 Jun;35(3):150-3 - PubMed
  30. J Urol. 2012 Apr;187(4):1280 - PubMed
  31. Am J Epidemiol. 2004 Jan 1;159(1):42-8 - PubMed
  32. BMC Urol. 2012 Nov 21;12:33 - PubMed
  33. J Res Pharm Pract. 2014 Jan;3(1):6-11 - PubMed
  34. N Engl J Med. 2012 Mar 15;366(11):1028-37 - PubMed
  35. BMC Infect Dis. 2012 Apr 18;12:92 - PubMed
  36. APMIS. 2004 Mar;112(3):159-64 - PubMed
  37. Duodecim. 2011;127(21):2334-5 - PubMed
  38. BMC Fam Pract. 2014 Sep 26;15:162 - PubMed
  39. Ann Clin Microbiol Antimicrob. 2013 Apr 29;12:8 - PubMed

Publication Types